Menu
Enrolling by invitation NCT02503228

Clinical Registry Assessment of the Missouri Osteochondral Allograft Preservation System - MOPS

Observational Symptomatic Osteochondral Defect(s) Cartilage, Meniscus, Ankle, Knee, Shoulder, Hip

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Standard of care osteochondral and or meniscal allograft transplantation.
Who it may be relevant to
Registry conditions: Symptomatic Osteochondral Defect(s), Cartilage, Meniscus, Ankle, Knee, Shoulder, Hip. Basic parameters: from 13 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Clinical Assessment of the Missouri Osteochondral Allograft Preservation System: Lifelong Registry

Overview

With institutional review board approval and informed consent, patients are prospectively enrolled into a registry to follow outcomes after osteochondral allograft (OCA) and/or meniscal allograft transplantation. Patients are included when 1 year followup data are available, including complications and reoperations, patient reported outcome measures (PROMs), compliance with rehabilitation, revisions, and failures. In addition, MOPS grafts are compared to standard preservation grafts, and unipolar, multisurface, and bipolar cohorts, as well as patient compliance variables, are compared.

Detailed description

With institutional review board approval and documented informed consent, patients are prospectively enrolled into a dedicated registry designed to follow outcomes after OCA transplantation with or without meniscal allograft transplantation. All grafts are obtained from tissue banks accredited by the American Association of Tissue Banks (AATB) and used in conformance of the tissue to the US Food and Drug Administration classification of a human cell and tissue product under section 361 of the Public Health Services Act. Initially, standard preservation (SP) grafts stored in refrigeration in proprietary solutions for 21 days after recovery from 1 of 3 AATB accredited tissue banks were used. As a separate arm, first clinical use of Missouri Osteochondral Preservation System (MOPS) grafts, which are stored at room temperature using MOPS methods for up to 56 days after recovery from 1 AATB accredited tissue bank, was assessed. In phase 2, after MOPS grafts became commercially available, type of graft implanted was based on patient-matched graft availability. Then, on the basis of emerging evidence published in the peer-reviewed medical literature, we implemented a shift in practice to discontinue use of SP grafts at our center.

Surgery is performed on patients with at least one large focal full-thickness articular cartilage defect and/or functional deficiency of 1 or both menisci for knee patients, and for hip, ankle or shoulder patients with at least 1 large focal full-thickness defect who chose this treatment option over other nonsurgical or surgical options as indicated and were approved for coverage by their insurance provider. OCA transplantation surgery is performed using press-fit cylindrical grafts and/or custom-cut patient-specific tab-in-slot shell grafts stabilized with either screws, bioabsorbable pins, or bioabsorbable nails. OCA bone is saturated with autogenous bone marrow aspirate concentrate (Angel System; Arthrex, Inc) immediately before implantation after subchondral drill holes are created and the donor bone is thoroughly lavaged to remove marrow elements. Meniscal allograft transplants (fresh or fresh frozen) are performed via a bone plug technique with suspensory fixation or included as part of the tibial OCA transplant. Viable chondrocyte density of OCAs at the time of transplantation are determined when tissues are available, as previously described. Procedure-specific postoperative management protocols are prescribed to each patient undergoing allograft transplantation. All patients receive oral and written instructions regarding postoperative rehabilitation.

Data are collected preoperatively and at 6 weeks, 3 months, 6 months, and yearly after surgery for each case. Demographic and operative data are collected from the electronic medical record. Patient-reported outcome measures (PROMs) are collected at each time point. All reported complications and reoperations are recorded in the electronic medical record. Revision is defined as a second operation to revise the osteochondral and/or meniscal allograft in at least 1 part of the patient's joint, and failure is defined as conversion to total or partial artificial joint arthroplasty, joint fusion, or amputation. The decision to pursue revision or failure surgery is based on the attending surgeon's discussion of joint pathology, treatment options, and related prognosis in conjunction with patient preference. Successful outcomes are defined as patients reporting return to functional activities with no need for revision or conversion surgery at last recorded follow-up. Descriptive statistics are calculated to report means, ranges, and percentages. On the basis of the difference in graft preservation methodology, cases are also analyzed by cohort as defined by SP versus MOPS. On the basis of surgery type, cases are also analyzed by cohort as defined by unipolar, multisurface, or bipolar transplants. Chi-square or Fisher exact tests are used to assess for significant differences in proportions. When significant differences in proportions are noted, odds ratios are calculated for relevant comparisons. One-way analysis of variance or t tests are used to assess for significant differences among cohorts at respective time points. Repeated measures analyses of variance are used to assess for significant differences within cohorts over time. Kaplan-Meier survival probability estimates with 95% CIs are calculated and compared. Significance is set at P\<.05.

Interventions

  • Procedure Standard of care osteochondral and or meniscal allograft transplantation
    Standard of care osteochondral and or meniscal allograft transplantation

Primary outcome measures

  • International Knee Documentation Committee (IKDC) [Time frame: annually up to 29 years]
  • PROMIS survey (PROMIS Bank v1.2 - Physical Function) [Time frame: annually up to 29 years]
  • Visual Analogue Scale (VAS) Pain Score [Time frame: annually up to 29 years]
  • Single Assessment Numeric Evaluation (SANE) [Time frame: annually up to 29 years]
  • Success, Revision, Failure [Time frame: annually up to 29 years]
  • PROMIS survey (PROMIS Bank v1.2 - Physical Function - Mobility [Time frame: annually up to 29 years]
Secondary outcome measures (4)
  • PROMIS survey (PROMIS Bank v1.1 - Pain Interference) [Time frame: annually up to 29 years]
  • Standard of Care (SOC) Diagnostic Imaging [Time frame: Pre-operative, 6 week, 3 month, 6 month, and annually up to 29 years]
  • Blood and Urine Samples [Time frame: Pre-operative, Day of Surgery, 6 week, 3 month, 6 month, and annually up to 29 years]
  • Non-SOC MRI [Time frame: 12 month visit]

Eligibility criteria

Inclusion criteria

  • Adults and children age ≥13 years
  • Knee, hip, ankle, or shoulder osteochondral defect ≥15mm as determined by MRI or diagnostic knee arthroscopy for allograft transplantation
  • Must be physically and mentally willing and able to comply with postoperative and routinely scheduled clinical and radiographic evaluations.
  • Must be able to read and understand English or a language for which translated versions of the patient reported questionnaires and Informed consent form are available.
  • Must be able to sign informed consent and must voluntarily sign the Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved subject Informed Consent Form.

Exclusion criteria

  • Is a prisoner
  • Is receiving workman's compensation
  • Subject is mentally incompetent such that would preclude the subject from providing adequate consent and/or complying with study requirements

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 1 center
  • University of Missouri — Columbia

Publications

  • Schreiner AJ, Stannard JP, Stoker AM, Bozynski CC, Kuroki K, Cook CR, Cook JL. Unicompartmental bipolar osteochondral and meniscal allograft transplantation is effective for treatment of medial compartment gonarthrosis in a canine model. J Orthop Res. 2021 May;39(5):1093-1102. doi: 10.1002/jor.24801. Epub 2020 Jul 27. PMID 32672863
  • Thomas DM, Stannard JP, Pfeiffer FM, Cook JL. Biomechanical Properties of Bioabsorbable Fixation for Osteochondral Shell Allografts. J Knee Surg. 2020 Apr;33(4):365-371. doi: 10.1055/s-0039-1677837. Epub 2019 Feb 6. PMID 30727021
  • Cook JL. Editorial Commentary: Bone Marrow Aspirate Biologics for Osteochondral Allografts-Because We Can or Because We Should? Arthroscopy. 2019 Aug;35(8):2445-2447. doi: 10.1016/j.arthro.2019.04.018. PMID 31395184
  • Baumann CA, Baumann JR, Bozynski CC, Stoker AM, Stannard JP, Cook JL. Comparison of Techniques for Preimplantation Treatment of Osteochondral Allograft Bone. J Knee Surg. 2019 Jan;32(1):97-104. doi: 10.1055/s-0038-1636834. Epub 2018 Mar 7. PMID 29514363
  • Cook JL, Stannard JP, Stoker AM, Bozynski CC, Kuroki K, Cook CR, Pfeiffer FM. Importance of Donor Chondrocyte Viability for Osteochondral Allografts. Am J Sports Med. 2016 May;44(5):1260-8. doi: 10.1177/0363546516629434. Epub 2016 Feb 26. PMID 26920431
  • Cook JL, Stoker AM, Stannard JP, Kuroki K, Cook CR, Pfeiffer FM, Bozynski C, Hung CT. A novel system improves preservation of osteochondral allografts. Clin Orthop Relat Res. 2014 Nov;472(11):3404-14. doi: 10.1007/s11999-014-3773-9. Epub 2014 Jul 17. PMID 25030100
  • Crist BD, Stoker AM, Pfeiffer FM, Kuroki K, Cook CR, Franklin SP, Stannard JP, Cook JL. Optimising femoral-head osteochondral allograft transplantation in a preclinical model. J Orthop Translat. 2015 Nov 25;5:48-56. doi: 10.1016/j.jot.2015.10.001. eCollection 2016 Apr. PMID 30035074
  • Garrity JT, Stoker AM, Sims HJ, Cook JL. Improved osteochondral allograft preservation using serum-free media at body temperature. Am J Sports Med. 2012 Nov;40(11):2542-8. doi: 10.1177/0363546512458575. Epub 2012 Sep 12. PMID 22972852

Identifiers

NCT: NCT02503228 · 2002628 · 2003053

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗